Evidence map›Paper›PMID 40568068›Full record

ArticlebioRxiv : the preprint server for biology2025

Single-cell-guided identification of logic-gated antigen combinations for designing effective and safe CAR therapy.

Sanna Madan, Tian-Gen Chang, Alexandra R Harris, Huaitian Liu, Andrew Martinez, Saugato Rahman Dhruba, Binbin Wang, Padma Sheila Rajagopal, Sanju Sinha, Aravind Srinivasan and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sanna MadanCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Tian-Gen ChangCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.ORCID 0000-0003-1485-1992
Alexandra R HarrisLaboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Huaitian LiuLaboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Andrew MartinezCedars-Sinai Medical Center, Los Angeles, CA USA.
Saugato Rahman DhrubaCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Binbin WangCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Padma Sheila RajagopalCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Sanju SinhaSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA USA.
Aravind SrinivasanDepartment of Computer Science, University of Maryland College Park, College Park, MD USA.
Simon R V KnottCedars-Sinai Medical Center, Los Angeles, CA USA.
Shahin SayedDepartment of Pathology, Aga Khan University, Nairobi, KENYA.
Francis MakokhaDirectorate of Research & Innovation, Mount Kenya University, Thika, KENYA.
Chi-Ping DayCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Gretchen L GierachIntegrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD USA.
Stefan AmbsLaboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Alejandro A SchäfferCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
Eytan RuppinCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies. However, its application in solid tumors remains limited because single targets are unlikely to suffice due to tumor antigen heterogeneity and off-tumor toxicities. To overcome these obstacles, we developed

Identifiers

PMID40568068
PMCPMC12191104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.